iD Bladder is an online resource providing information on PD-L1 testing in patients with bladder cancer, including evidence to support the importance of testing and useful guidance on how and when to test.
Anti-PD-1/PD-L1 immunotherapy has been associated with antitumour activity in patients with UC.1–4
Recent studies have suggested a role for PD-L1 expression in identifying patients more likely to benefit from immunotherapy-based treatment regimens.1–3
Several IHC assays are available to stain samples for PD-L1 expression.5 Scoring algorithms are applied to stained samples to classify them as PD-L1 high or low/negative. These algorithms are specific to the intended immunotherapy.6–10